IL17A and psoriasis: Biologic agents such as interleukin-17 (IL-17) inhibitors are increasingly used for the management of moderate-to-severe psoriasis due to their ability to achieve similar therapeutic outcomes with better safety profiles than conventional systemic treatments, such as methotrexate or cyclosporine.